N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128-3p/MAPK1 axis.

导出 LinkOut

翻译打印收藏纠错

作者： Jiahe,Yi ^[1] ; Xueyou,Ma ^[1] ; Yufan,Ying ^[1] ; Zixiang,Liu ^[1] ; Yijie,Tang ^[1] ; Xuan,Shu ^[1] ; Jiazhu,Sun ^[1] ; Yuqing,Wu ^[1] ; Dingheng,Lu ^[1] ; Xiao,Wang ^[1] ; Jindan,Luo ^[1] ; Ben,Liu ^[1] ; Xiangyi,Zheng ^[1] ; Yiwei,Lin ^[2] ; Jiangfeng,Li ^[3] ; Liping,Xie ^[4]

作者单位： Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China. ^[1] Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China. Electronic address: zjulyw@zju.edu.cn. ^[2] Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China. Electronic address: lijf@zju.edu.cn. ^[3] Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Center, Zhejiang University, Hangzhou, 310058 China. Electronic address: xielp@zju.edu.cn. ^[4]

关键词 Bladder cancer progression MAPK1 circPSMA7 m(6)A modification miR-128–3p